Related Experiment Video
Updated: May 24, 2026
07:20
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Are novel serum biomarkers informative?
John T Wilkins1, Donald M Lloyd-Jones
1Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
The Medical Clinics of North America
|March 7, 2012
Summary
No new serum biomarker has yet improved coronary heart disease (CHD) risk assessment beyond current methods. Further research is needed to enhance CHD risk prediction and clinical decision-making capabilities.
Area of Science:
- Cardiovascular Medicine
- Biomarker Discovery
- Preventive Cardiology
Background:
- Current coronary heart disease (CHD) risk assessment relies on probabilistic methods that are imperfect.
- Existing population-based risk stratification approaches have not been substantially improved by novel serum biomarkers.
- Limited clinical trial data exist to evaluate the true utility of novel biomarkers in risk assessment.
Purpose of the Study:
- To evaluate the criteria for incorporating novel serum biomarkers into routine coronary heart disease (CHD) risk assessment.
- To determine if novel biomarkers provide additional predictive information beyond current risk assessment techniques.
- To highlight the need for continued research in CHD biomarker development.
Main Methods:
- Review of existing literature on serum biomarkers and CHD risk assessment.
- Analysis of the requirements for a biomarker to be clinically useful in risk stratification.
- Evaluation of the current limitations in CHD risk prediction models.
Main Results:
- No novel serum biomarker has demonstrated significant improvement over current CHD risk stratification methods.
- The specific association of a biomarker with future CHD events is crucial for its justification.
- Biomarkers have the potential to enhance clinical decision-making, despite current limitations.
Conclusions:
- Novel serum biomarkers must offer specific associations with future CHD events and add value beyond existing methods.
- Further basic science and population-based research are essential to advance CHD risk assessment capabilities.
- The integration of validated biomarkers could improve the accuracy of predicting coronary heart disease.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:24Serum Studies: Renal Function Tests
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.